Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)
This study is currently recruiting participants.
Study NCT00391066
Information provided by Biogen Idec
First Received: October 19, 2006
Last Updated: September 25, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
